Talphera (NASDAQ:TLPH) Stock Price Down 1.9% – Here’s What Happened

Talphera, Inc. (NASDAQ:TLPH) dropped 1.9% during trading on Friday . The company traded as low as $0.60 and last traded at $0.60. Approximately 48,096 shares changed hands during trading, a decline of 42% from the average daily volume of 83,511 shares. The stock had previously closed at $0.61.

Wall Street Analysts Forecast Growth

TLPH has been the topic of several recent analyst reports. RODMAN&RENSHAW upgraded shares of Talphera to a “strong-buy” rating in a report on Tuesday, January 28th. Maxim Group upgraded shares of Talphera to a “strong-buy” rating in a report on Friday, November 8th. Rodman & Renshaw initiated coverage on Talphera in a report on Tuesday, January 28th. They set a “buy” rating and a $4.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $6.00 target price on shares of Talphera in a report on Tuesday, January 21st.

Talphera Price Performance

The business’s 50-day simple moving average is $0.62 and its two-hundred day simple moving average is $0.78. The stock has a market capitalization of $10.23 million, a price-to-earnings ratio of -0.87 and a beta of 0.29.

Hedge Funds Weigh In On Talphera

An institutional investor recently bought a new position in Talphera stock. Rosalind Advisors Inc. acquired a new stake in Talphera, Inc. (NASDAQ:TLPH) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 758,966 shares of the company’s stock, valued at approximately $650,000. Talphera accounts for approximately 0.4% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 25th biggest holding. Rosalind Advisors Inc. owned about 4.47% of Talphera at the end of the most recent quarter. Institutional investors and hedge funds own 37.67% of the company’s stock.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.